Oncology Learning NetworkPhase 3 PROTEUS Trial Establishes New Standard of Care for High-Risk Localized Prostate Cancer

The phase 3 PROTEUS trial randomized patients with newly diagnosed high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy with pelvic lymph node dissection to perioperative apalutamide plus ADT or placebo plus ADT for six months before and after surgery. Relapse rates in high-risk localized prostate cancer can approach 70% with surgery alone, establishing the rationale for systemic intensification around resection.

Clinical Considerations

• Major pathologic response (pCR or minimal residual disease) was ninefold higher with apalutamide plus ADT vs. placebo plus ADT (30% vs. 11%); residual cancer burden endpoint also significantly favored the combination
• Metastasis-free survival showed a 20% reduction in events with apalutamide plus ADT (HR 0.80); investigator-assessed MFS showed a 26% reduction (HR 0.74)
• Time to subsequent therapy was reduced by 33%, with nearly a 3-year difference between arms, translating to meaningful delay in downstream ADT and pelvic radiation exposure
• Overall survival data were not reported; long-term survival benefit remains to be established with continued follow-up

Practice Applications

• Recognize perioperative apalutamide plus ADT as a practice-shaping phase 3 signal for high-risk localized disease, which is distinct from the castration-sensitive metastatic setting addressed in TALAPRO-3
• Note this trial enrolled an unselected population (no HRR mutation requirement), broadening potential applicability relative to biomarker-gated trials in the same disease space
• Monitor for peer-reviewed publication and FDA submission; plenary LBA1 designation at ASCO signals regulatory pathway prioritization
• Anticipate multidisciplinary treatment planning conversations between urology and medical oncology will need to incorporate perioperative systemic therapy timing as this data matures